Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
about
Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.Biophysical Properties and Motility of Human Mature Dendritic Cells Deteriorated by Vascular Endothelial Growth Factor through Cytoskeleton Remodeling.Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Shaping of Peripheral T Cell Responses by Lymphatic Endothelial Cells.In Vivo Imaging Sheds Light on Immune Cell Migration and Function in Cancer.Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.Cancer Immunotherapy: Whence and Whither.Dendritic cells in cancer: the role revisited.Functions of Murine Dendritic Cells.Dendritic Cells and Cancer Immunity.TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccinesLymphatic Vessels Balance Viral Dissemination and Immune Activation following Cutaneous Viral InfectionMetagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma PatientsLoss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response.Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.FOXOs in Cancer Immunity: Knowns and Unknowns.Informatics for cancer immunotherapy.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Integration of nano drug-delivery system with cancer immunotherapy.Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model.Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.Innate and acquired immune surveillance in the postdissemination phase of metastasis.NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.Understanding the tumor immune microenvironment (TIME) for effective therapy.Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma.Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.CD103+ cells at the forefront of anticancer immunity.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer.
P2860
Q30830664-93BD785C-5A52-4968-AA20-C86D436CED93Q36181047-E8B0C96A-312A-4B25-B3E4-79AA3AC7EC4EQ37473978-D2A65CAE-F535-416F-86B4-C3C2EDABB5C4Q37541609-738299E3-9A89-4569-ACFE-751EE72A5ECAQ37554718-85E82E6B-7750-4731-A9E1-403BA1196C2EQ37580778-F83B9BBE-CB57-4585-A630-59B53626CE3AQ37714428-03AA6A0E-EF9E-4C08-8066-8B1A0EE239E0Q38704192-CC14416C-05D1-42E7-9344-87B027BFE533Q38737924-673F0097-8D79-4999-A478-F2F7D467A90FQ38963934-AA4EBB1F-53FF-4A15-9858-795B9F34EB3DQ38985483-B085F75F-9C5B-4F06-888A-CD11BC9EF157Q38994017-18FF3E6F-6BAA-4F59-AF55-658B8C287B61Q39160959-8D4DF62B-800C-4E49-A01A-217B8743F316Q39448911-7B903F38-A901-4671-91AD-A0094776196DQ41664330-A349F4F5-EDBE-4B2C-9DBF-8F4D13321F4FQ41693862-558DDB7C-9F33-4216-9A2F-6EB702A56B76Q41718028-B7553594-3BA4-4C56-ADE6-D9EBE81EEF09Q41930681-8118BED6-A446-4938-8B88-3809D20AB637Q42378527-2F1A8D74-9351-4459-95FA-8A17ED5F142FQ47134263-7D6330B3-A877-4D30-BB15-BB6C173022A0Q47224295-DA80E622-22D9-4431-80BD-7E303DD1492CQ47290509-30D153B0-1DE5-43FB-A220-3C54107FD0D1Q48308048-37291FB2-EAC7-4CC4-A46A-495F5E4C5D8AQ48622958-30879DBF-B5B2-4EBF-BAC5-FBE592E55C4EQ49710218-253D2211-EC0C-4714-9D98-FE1B6E09333FQ49737040-00C0E04C-219F-4B08-90F2-921DD45B26C6Q50048813-F154E916-DB50-4708-87BD-77E93CC35B32Q50076191-685FA5B5-3291-491E-9564-2F084FA5BFC1Q50420406-68B71EAA-8E0B-4297-8466-E3FEC8667547Q50647447-EA489D27-9017-4941-9128-005C4A044EC6Q50676824-C960755F-D869-4820-B920-BAB77391F3AAQ52311744-4C9A3967-61CF-49EC-BD25-AB70D0EAE6BDQ52606149-A60994C1-CF2D-47D6-92E5-407CF9E2C59AQ52720866-7D3DA09B-3EE0-4B1D-AAB2-07AB8A889D2EQ52723482-2E91C19F-79ED-4099-8218-F37D83999568Q52726024-80254B10-DA90-467C-BC74-EE658CA17C08Q52780158-40B2C151-6010-465B-8005-09FA34E0317BQ52801913-530A6D16-E727-407E-8D92-8A429D727185Q54961397-88715F63-DAF9-45C2-BB35-544053E31DF4Q54977101-95FE8380-9DFF-4BEB-87DB-45064E66EC14
P2860
Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.
@ast
Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.
@en
type
label
Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.
@ast
Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.
@en
prefLabel
Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.
@ast
Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.
@en
P2093
P2860
P1433
P1476
Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.
@en
P2093
Amanda E Nelson
Denise M Wolf
Dusan Bogunovic
Matthew F Krummel
Mikhail Binnewies
Miranda L Broz
Nina Bhardwaj
Tsuneyasu Kaisho
P2860
P304
P356
10.1016/J.CCELL.2016.06.003
P577
2016-07-09T00:00:00Z